<DOC>
	<DOCNO>NCT00005819</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose combination chemotherapy treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose combination fenretinide , paclitaxel , cisplatin patient advance solid tumor . - Determine effect fenretinide pharmacokinetics paclitaxel cisplatin . - Assess relationship dose plasma level fenretinide safety antitumor effect , term overall response , response rate , progression-free survival rate , patient . OUTLINE : This dose-escalation study paclitaxel cisplatin . Patients receive oral fenretinide twice daily 7 day . Patients receive paclitaxel IV 3 hour cisplatin IV 30 minute day 7 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive paclitaxel cisplatin recommend phase II dose . PROJECTED ACCRUAL : Approximately 15-24 patient accrue study within 12-24 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor amenable conventional surgery , radiotherapy , chemotherapy No brain metastases primary brain tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 9.0 g/dL Hepatic : Bilirubin le 1.6 mg/dL AST ALT less 2 time upper limit normal PT PTT normal OR INR le 1.1 Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No extensive sign macular degeneration , include exudative atrophic macular lesion reduce correct vision less 20/40 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Prior platinumcontaining agent taxane exposure allow evidence neurotoxicity Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover Surgery : Not specify Other : No concurrent vitamin A supplement No concurrent supplemental antioxidant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>